Screener Summaries Updates Institutions Sign In More Updates › Other Events › CRVO Other Events · Jul 9, 2026
CervoMed Inc. announced on July 9, 2026, that it has completed enrollment in its Phase 2a clinical study of… CRVO CervoMed Inc.
CervoMed Inc. announced on July 9, 2026, that it has completed enrollment in its Phase 2a clinical study of neflamapimod for treating nonfluent variant primary progressive aphasia, a form of frontotemporal dementia. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.
More from CervoMed Inc. CervoMed reports mean plasma NfL reduction of ~5.7 pg/mL in Phase 2a nfvPPA trial Oct 13, 2026 CervoMed Inc. announced that its drug candidate neflamapimod has been granted an Innovation Passport to enter the UK’s… Aug 4, 2026 CervoMed Inc. announced clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, in… Jul 14, 2026 CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share Jun 22, 2026 On June 18, 2026, CervoMed Inc. entered into a Securities Purchase Agreement for a registered direct offering of… Jun 18, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
